Michelle H Schmidt

US Patent:

8097733, Jan 17, 2012

Filed:

Nov 24, 2008

Appl. No.:

12/276779

Inventors:

Edgardo Alvira - O'Fallon MO, US
Matthew J. Graneto - Chesterfield MO, US
Margaret Lanahan Grapperhaus - Troy IL, US
Kaliappan Iyanar - Ballwin MO, US
Todd Michael Maddux - Portage MI, US
Matthew William Mahoney - St. Peters MO, US
Mark Alan Massa - Chesterfield MO, US
Kirby Ray Sample - St. Louis MO, US
Michelle Ann Schmidt - Millstadt IL, US
Ronald Edward Seidel - Creve Coeur MO, US
Jon Gordon Selbo - Wentzville MO, US
Michael Brent Tollefson - Dardenne Prairie MO, US
Richard Alan Vonder Embse - St. Louis MO, US
Grace Mary Wagner - Webster Groves MO, US
Scott Santford Woodard - Manchester MO, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 231/10

US Classification:

5483771

Abstract:

The invention relates to compounds of formula (I).

US Patent:

20050209278, Sep 22, 2005

Filed:

Nov 3, 2003

Appl. No.:

10/700202

Inventors:

Joseph McDonald - Wildwood MO, US
Darren Kassab - O'Fallon MO, US
Mark Massa - Ballwin MO, US
Margaret Grapperhaus - Troy IL, US
Michelle Schmidt - Belleville IL, US
Joseph Rico - O'Fallon MO, US
Patrick Mullins - St. Louis MO, US
David Brown - Chesterfield MO, US

International Classification:

A61K031/452
C07D045/02

US Classification:

514317000, 514326000, 546207000, 546216000, 544392000

Abstract:

This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A, A, Y, E, E, E, and Rare as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.

US Patent:

20210002251, Jan 7, 2021

Filed:

Sep 18, 2020

Appl. No.:

17/025026

Inventors:

- New York NY, US
Balekudru Devadas - Chesterfield MO, US
Danny James Garland - House Springs MO, US
Margaret Lanahan Grapperhaus - Troy IL, US
Seungil Han - Mystic CT, US
Susan Landis Hockerman - Kirkwood MO, US
Robert Owen Hughes - Newtown CT, US
Eddine Saiah - Brookline MA, US
Mark Edward Schnute - Acton MA, US
Shaun Raj Selness - Chesterfield MO, US
Daniel Patrick Walker - Augusta MO, US
Li Xing - Lexington MA, US
Christoph Wolfgang Zapf - Marlborough MA, US
Michelle Ann Schmidt - Millstadt IL, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 401/04

Abstract:

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

US Patent:

20190202798, Jul 4, 2019

Filed:

Mar 8, 2019

Appl. No.:

16/296319

Inventors:

- New York NY, US
Balekudru Devadas - Chesterfield MO, US
Danny James Garland - House Springs MO, US
Margaret Lanahan Grapperhaus - Troy IL, US
Seungil Han - Mystic CT, US
Susan Landis Hockerman - Kirkwood MO, US
Robert Owen Hughes - Newtown CT, US
Eddine Saiah - Brookline MA, US
Mark Edward Schnute - Acton MA, US
Shaun Raj Selness - Chesterfield MO, US
Daniel Patrick Walker - Augusta MO, US
Li Xing - Lexington MA, US
Christoph Wolfgang Zapf - Marlborough MA, US
Michelle Ann Schmidt - Millstadt IL, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 401/04

Abstract:

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases cases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

US Patent:

20170283393, Oct 5, 2017

Filed:

Jun 16, 2017

Appl. No.:

15/624969

Inventors:

- New York NY, US
Balekudru Devadas - Chesterfield MO, US
Danny James Garland - House Springs MO, US
Margaret Lanahan Grapperhaus - Troy IL, US
Seungil Han - Mystic CT, US
Susan Landis Hockerman - Kirkwood MO, US
Robert Owen Hughes - Newtown CT, US
Eddine Saiah - Brookline MA, US
Mark Edward Schnute - Acton MA, US
Shaun Raj Selness - Chesterfield MO, US
Daniel Patrick Walker - Augusta MO, US
Li Xing - Lexington MA, US
Christoph Wolfgang Zapf - Marlborough MA, US
Michelle Ann Schmidt - Millstadt IL, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 401/04

Abstract:

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

US Patent:

20150291554, Oct 15, 2015

Filed:

Nov 1, 2013

Appl. No.:

14/439478

Inventors:

- New York NY, US
Balekudru Devadas - Chesterfield MO, US
Danny James Garland - House Springs MO, US
Margaret Lanahan Grapperhaus - Troy IL, US
Seungil Han - Mystic CT, US
Susan Landis Hockerman - Kirkwood MO, US
Robert Owen Hughes - Newtown CT, US
Eddine Saiah - Brookline MA, US
Mark Edward Schnute - Acton MA, US
Shaun Raj Selness - Chesterfield MO, US
Daniel Patrick Walker - Augusta MO, US
Li Xing - Lexington MA, US
Christoph Wolfgang Zapf - Marlborough MA, US
Michelle Ann Schmidt - Millstadt IL, US

International Classification:

C07D 401/04

Abstract:

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Author:

Michelle Schmidt

ISBN #:

0671524909